ijo
www.spandidos-publications.com
Home  | About  | Contact
Spandidos Logo
Advanced Search
Login  | Register


congress_banner

main_table_top_image
   Current Issue Early Online Archive Manuscript Submission About Editor and Editorial Academy Sitemap
Expression of CD24 in cholangiocarcinoma cells is associated with disease progression and reduced patient survival

Authors:
Siriporn Keeratichamroen, Kawin Leelawat, Taweesak Thongtawee, Siriluck Narong, Umaad Aegem, Supathip Tujinda, Niphon Praditphol, Rutaiwan Tohtong

Affiliations:
Department of Molecular Medicine, Faculty of Science, Mahidol University, Bangkok 10400, Thailand, Department of Surgery, Rajavithi Hospital, Bangkok 10400, Thailand

Published online on:
Friday, June 17, 2011

Doi:
10.3892/ijo.2011.1088

Pages:
873-881

Abstract:

Cholangiocarcinoma is frequently found to invade local tissues and metastasize to distal organs. We investigated the expression of CD24 in cholangiocarcinoma samples and its prognostic significance. In addition, the cellular function of CD24 was studied in the RMCCA1 cholangiocarcinoma cell line. High CD24 expression significantly correlated with lymph node metastasis and positive surgical margins in cholangiocarcinoma patients. Univariate and multivariate analyses further demonstrated that CD24 expression was significantly associated with the overall survival of these patients (p=0.007 and p=0.040, respectively). For in vitro studies, the magnetic-activated cell sorting (MACS) system was used to isolate CD24+ and CD24- cell populations from RMCCA1 cells. CD24+ RMCCA1 cells had increased chemoresistance, adhesion (p=0.004), motility (p<0.001), migration (p<0.001) and invasion (p<0.001) capabilities when compared to CD24- cells. The matrix metalloproteinase (MMP)-7 was significantly elevated in CD24+ RMCCA1 cells (p=0.01). We found that inhibition of CD24 using siRNA silencing significantly decreased the invasive capacity of RMCCA1 cells. Both clinical and in vitro studies suggest that expression of CD24 is associated with cholangiocarcinoma disease progression. CD24 may thus serve as a new target for directed molecular therapy of cholangiocarcinoma.

International Journal of Oncology

October 2011
Volume 39 Number 4


Viewing options: Sign up for eToc alerts
Recommend to Library

Share this article:




main_table_bottom_image